Mentor Capital Cancer Immunotherapy Index Outpaces Biotechs on Second Anniversary

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index has appreciated 85.30% during the twenty-four months since its creation on July 10, 2009. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the similar two-year period the biotech indices averaged a 79.85% gain. In comparison, the Cancer Immunotherapy Index gain of 85.30% was appreciating at 107% of the overall biotech average.

Immunocellular Therapeutics (617%), Oncothyreon (174%) and Dendreon (76%) have led the sector in gains over its two-year history. Cancer immunotherapy pioneer, Dendreon, also dominates the market capitalization of the sector, representing 86% of the combined Cancer Immunotherapy Index total share value of $6.7 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their reported two-year gain since Index formation on July 10, 2009 follow: Dendreon (NASDAQ:DNDN) +76.37%, Immunocellular Therapeutics, Ltd. (OTCBB:IMUC) +616.67%, Oncothyreon (NASDAQ:ONTY) +173.71%, Agenus (NASDAQ:AGEN) -46.41%, Biovest International (BVTI.PK) +42.86%, Celldex Therapeutics (NASDAQ:CLDX) -48.03%, Northwest Biotherapeutics (OTCBB:NWBO) -9.33%, CEL - SCI Corp. (AMEX:CVM) +25.00%, Generex Biotechnology (NASDAQ:GNBT) -60.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) -1.02% since February 22, 2010 and Advaxis, Inc., +38.46% since it was added to the Index February 12, 2011 - all for an average two-year gain of 85.30%.

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge cancer companies. Mentor maintains a tracking position in all companies in the Cancer Immunotherapy Index. In its efforts to support the development of the best in cancer solutions, Mentor Capital management attempts to significantly overweight its positions in those Index and other cancer companies it views with the greatest medical and financial promise. The Index company summaries can be tracked through updates of the Cancer Immunotherapy Index presented at

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

    Source: Mentor Capital, Inc.